Summary
2.65 -0.04(-1.49%)10/04/2024
Repro-Med Systems, Inc. (KRMD)
Repro-Med Systems, Inc. (KRMD)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.49 | -3.81 | 9.96 | 4.74 | 6.85 | -1.12 | -28.38 | 2,309.09 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 2.65 | |
| Open | 2.59 | |
| High | 2.69 | |
| Low | 2.59 | |
| Volume | 3,464 | |
| Change | -0.04 | |
| Change % | -1.49 | |
| Avg Volume (20 Days) | 112,745 | |
| Volume/Avg Volume (20 Days) Ratio | 0.03 | |
| 52 Week Range | 1.98 - 3.09 | |
| Price vs 52 Week High | -14.24% | |
| Price vs 52 Week Low | 33.84% | |
| Range | 2.38 | |
| Gap Up/Down | -0.15 | |
Fundamentals | ||
| Market Capitalization (Mln) | 124 | |
| EBIDTA | 1,681,882 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 4.67 | |
| Book Value | 0.8270 | |
| Earnings Per Share | -0.0990 | |
| EPS Estimate Current Quarter | -0.0200 | |
| EPS Estimate Next Quarter | -0.0200 | |
| EPS Estimate Current Year | -0.1000 | |
| EPS Estimate Next Year | -0.1200 | |
| Diluted EPS (TTM) | -0.0990 | |
| Revenues | ||
| Profit Marging | -0.2056 | |
| Operating Marging (TTM) | -0.2094 | |
| Return on asset (TTM) | -0.0635 | |
| Return on equity (TTM) | -0.1128 | |
| Revenue TTM | 21,056,888 | |
| Revenue per share TTM | 0.4750 | |
| Quarterly Revenue Growth (YOY) | -0.0070 | |
| Quarterly Earnings Growth (YOY) | -0.6600 | |
| Gross Profit (TTM) | 15,006,945 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 188.6792 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.8630 | |
| Revenue Enterprise Value | 5.5431 | |
| EBITDA Enterprise Value | 80.3702 | |
| Shares | ||
| Shares Outstanding | 44,561,200 | |
| Shares Float | 25,271,079 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 11.50 | |
| Institutions (%) | 58.34 | |
08/07 20:52 EST - seekingalpha.com
KORU Medical Systems, Inc (KRMD) Q2 2024 Earnings Call Transcript
KORU Medical Systems, Inc (KRMD) Q2 2024 Earnings Call Transcript
KORU Medical Systems, Inc (KRMD) Q2 2024 Earnings Call Transcript
KORU Medical Systems, Inc (KRMD) Q2 2024 Earnings Call Transcript
08/07 18:41 EST - zacks.com
KORU Medical Systems Inc. (KRMD) Reports Q2 Loss, Tops Revenue Estimates
KORU Medical Systems Inc. (KRMD) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.05 per share a year ago.
KORU Medical Systems Inc. (KRMD) Reports Q2 Loss, Tops Revenue Estimates
KORU Medical Systems Inc. (KRMD) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.05 per share a year ago.
07/31 11:06 EST - zacks.com
Will KORU Medical Systems Inc. (KRMD) Report Negative Earnings Next Week? What You Should Know
KORU Medical Systems Inc. (KRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will KORU Medical Systems Inc. (KRMD) Report Negative Earnings Next Week? What You Should Know
KORU Medical Systems Inc. (KRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
07/03 13:30 EST - zacks.com
KORU Medical's (KRMD) FreedomEdge Gets Regulatory Nod in Japan
KORU Medical (KRMD) announces the receipt of regulatory clearance for its FreedomEdge System in Japan.
KORU Medical's (KRMD) FreedomEdge Gets Regulatory Nod in Japan
KORU Medical (KRMD) announces the receipt of regulatory clearance for its FreedomEdge System in Japan.
06/05 09:00 EST - businesswire.com
Simplifying Subcutaneous Drug Administration: SCHOTT Pharma and KORU Medical Systems Announce Collaboration to Advance Large Volume Subcutaneous Infusion
MAINZ, Germany, & MAHWAH, N.J.--(BUSINESS WIRE)--SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, and KORU Medical Systems (NASDAQ: KRMD), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, are joining forces to offer a high-volume subcutaneous drug infusion solution. “We want to ensure that medications are safe and easy to use for.
Simplifying Subcutaneous Drug Administration: SCHOTT Pharma and KORU Medical Systems Announce Collaboration to Advance Large Volume Subcutaneous Infusion
MAINZ, Germany, & MAHWAH, N.J.--(BUSINESS WIRE)--SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, and KORU Medical Systems (NASDAQ: KRMD), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, are joining forces to offer a high-volume subcutaneous drug infusion solution. “We want to ensure that medications are safe and easy to use for.
06/04 16:03 EST - businesswire.com
KORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a collaboration with a global pharmaceutical company to initiate a feasibility study with KORU Medical's Freedom Infusion System (the “Freedom System”) for an FDA and EMA approved subcutaneous onco.
KORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a collaboration with a global pharmaceutical company to initiate a feasibility study with KORU Medical's Freedom Infusion System (the “Freedom System”) for an FDA and EMA approved subcutaneous onco.
05/14 16:05 EST - businesswire.com
KORU Medical Systems Signs Supply Agreement for a Phase III Clinical Trial for a Novel Endocrinological Biologic
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased to announce the signing of a Phase III clinical supply agreement for a novel enzyme replacement therapy to treat a rare endocrinological disease. This significant milestone marks the progression of this.
KORU Medical Systems Signs Supply Agreement for a Phase III Clinical Trial for a Novel Endocrinological Biologic
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased to announce the signing of a Phase III clinical supply agreement for a novel enzyme replacement therapy to treat a rare endocrinological disease. This significant milestone marks the progression of this.
05/01 22:11 EST - seekingalpha.com
KORU Medical Systems, Inc. (KRMD) Q1 2024 Earnings Call Transcript
KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Louisa Smith - The Gilmartin Group Linda Tharby - President & Chief Executive Officer Tom Adams - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Chase Knickerbocker - Craig-Hallum William Wood - B. Riley Securities Caitlin Cronin - Canaccord Genuity Joseph Downing - Piper Sandler Operator Greetings and welcome to the KORU Medical Systems' First Quarter 2024 Financial Results Conference Call and Webcast.
KORU Medical Systems, Inc. (KRMD) Q1 2024 Earnings Call Transcript
KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Louisa Smith - The Gilmartin Group Linda Tharby - President & Chief Executive Officer Tom Adams - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Chase Knickerbocker - Craig-Hallum William Wood - B. Riley Securities Caitlin Cronin - Canaccord Genuity Joseph Downing - Piper Sandler Operator Greetings and welcome to the KORU Medical Systems' First Quarter 2024 Financial Results Conference Call and Webcast.
05/01 19:21 EST - zacks.com
KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates
KORU Medical Systems Inc. (KRMD) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.05 per share a year ago.
KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates
KORU Medical Systems Inc. (KRMD) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.05 per share a year ago.
05/01 16:05 EST - businesswire.com
KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights First quarter 2024 net revenues of $8.2 million, an 11% increase over the prior year and record high quarterly revenue.
KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights First quarter 2024 net revenues of $8.2 million, an 11% increase over the prior year and record high quarterly revenue.
04/17 07:00 EST - businesswire.com
KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report first quarter 2024 financial results on Wednesday, May 1, 2024. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the fina.
KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report first quarter 2024 financial results on Wednesday, May 1, 2024. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the fina.
04/11 16:05 EST - businesswire.com
KORU Medical Systems Announces Successful Appeal in EU Notified Body Review
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a successful appeal related to an ongoing audit by its notified body in the EU, The British Standards Institute (BSI). The Company's appeal of an assessment report from BSI regarding a recommendati.
KORU Medical Systems Announces Successful Appeal in EU Notified Body Review
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a successful appeal related to an ongoing audit by its notified body in the EU, The British Standards Institute (BSI). The Company's appeal of an assessment report from BSI regarding a recommendati.
03/28 14:28 EST - investorplace.com
The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness
In most cases, investors should stay away from penny stocks. They're wild, they're unpredictable and they tend to lose their stakeholders money more so than they return.
The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness
In most cases, investors should stay away from penny stocks. They're wild, they're unpredictable and they tend to lose their stakeholders money more so than they return.
03/18 17:24 EST - businesswire.com
KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased to announce data on the impact of the Freedom Infusion System on subcutaneous immunoglobulin (SCIg) therapy for primary immunodeficiency diseases (PIDD) to be presented at the National Home Infusion Ass.
KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased to announce data on the impact of the Freedom Infusion System on subcutaneous immunoglobulin (SCIg) therapy for primary immunodeficiency diseases (PIDD) to be presented at the National Home Infusion Ass.
03/13 20:27 EST - seekingalpha.com
KORU Medical Systems, Inc. (KRMD) Q4 2023 Earnings Call Transcript
KORU Medical Systems, Inc. (KRMD) Q4 2023 Earnings Call Transcript
KORU Medical Systems, Inc. (KRMD) Q4 2023 Earnings Call Transcript
KORU Medical Systems, Inc. (KRMD) Q4 2023 Earnings Call Transcript
03/13 16:05 EST - businesswire.com
KORU Medical Systems, Inc. Announces 2023 Fourth Quarter, Full Year Financial Results, and 2024 Guidance
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the fourth quarter and full year ended December 31, 2023. The Company also issued guidance for the full year 2024. Recent Highlights Fourth quarter 2023 net revenues of $7.2 mi.
KORU Medical Systems, Inc. Announces 2023 Fourth Quarter, Full Year Financial Results, and 2024 Guidance
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the fourth quarter and full year ended December 31, 2023. The Company also issued guidance for the full year 2024. Recent Highlights Fourth quarter 2023 net revenues of $7.2 mi.
03/12 09:26 EST - zacks.com
KORU Medical (KRMD) Forms New Deal on Subcutaneous Infusion
One key aspect of the collaboration of KORU Medical (KRMD) with a pharmaceutical manufacturer is the exploration of new therapeutic settings.
KORU Medical (KRMD) Forms New Deal on Subcutaneous Infusion
One key aspect of the collaboration of KORU Medical (KRMD) with a pharmaceutical manufacturer is the exploration of new therapeutic settings.
03/11 16:05 EST - businesswire.com
KORU Medical Systems Announces a Feasibility Study to Enter Ambulatory Infusion Settings with a Commercialized Biologic
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a collaboration with a global pharmaceutical manufacturer to initiate a feasibility study with KORU's Freedom Infusion System for an already commercialized rare disease therapy. Upon successful com.
KORU Medical Systems Announces a Feasibility Study to Enter Ambulatory Infusion Settings with a Commercialized Biologic
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a collaboration with a global pharmaceutical manufacturer to initiate a feasibility study with KORU's Freedom Infusion System for an already commercialized rare disease therapy. Upon successful com.
03/06 07:00 EST - businesswire.com
KORU Medical Systems Signs a Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for a Novel Subcutaneous Immunoglobulin
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased to announce a clinical supply agreement for a novel subcutaneous immunoglobulin (SCIg) drug entering Phase 3 trials. The custom product developed for this clinical trial under a prior agreement was buil.
KORU Medical Systems Signs a Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for a Novel Subcutaneous Immunoglobulin
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased to announce a clinical supply agreement for a novel subcutaneous immunoglobulin (SCIg) drug entering Phase 3 trials. The custom product developed for this clinical trial under a prior agreement was buil.
02/21 07:00 EST - businesswire.com
KORU Medical Systems to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients, today announced that the Company will report fourth quarter and full year 2023 financial results on Wednesday, March 13, 2024. KORU Medical's management will host a conference call and webca.
KORU Medical Systems to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients, today announced that the Company will report fourth quarter and full year 2023 financial results on Wednesday, March 13, 2024. KORU Medical's management will host a conference call and webca.